Literature DB >> 1394042

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.

F Jänicke1, M Hölscher, W Kuhn, R von Hugo, L Pache, J R Siewert, H Graeff.   

Abstract

BACKGROUND: There is plenty of evidence that survival time associated with advanced ovarian cancer is predominantly related to the amount of residual tumor after primary operation. However, there are only few and inconclusive reports concerning the effect of second debulking procedures on survival time after relapse.
METHODS: To evaluate the effect of radical second operation, 30 patients with clinically diagnosed relapses had second operations after a median recurrence-free interval of 16 months. Considerable efforts were made to resect all tumor tissue. Complete resection was achieved in 14 of 39 (47%) patients, and residual tumors smaller than 2 cm remained in 12 (40%) patients. In 19 (63%) patients, intestinal resections were necessary. Operation time, blood units needed, hospital stay, and complication rates were comparable to those associated with primary debulking procedures.
RESULTS: Survival time after second operation was closely correlated with the residual tumor remaining after second surgical procedure and also with the length of the recurrence-free interval. Patients with complete resections had significantly longer survival times than those with residual tumors of less than 2 cm (median, 29 months versus 9 months; P = 0.004). Patients with a recurrence-free interval of more than 12 months had a longer survival time than those with a shorter disease-free time (median, 29 months versus 8 months; P = 0.002). Postoperative treatment also was shown to influence survival time, whereas grade of the tumor (P = 0.74), age of the patient (P = 0.87), and initial FIGO stage (P = 0.58) had no influence on survival time after second operation. Multivariate analysis (Cox regression) revealed that residual tumor after second surgical procedure (relative risk, 4.7) was the most important independent variable predicting survival time after second surgical procedure. Recurrence-free interval (relative risk, 2.7) and postoperative (second-line) treatment (relative risk, 3.0) were equally potent variables. Residual tumor after primary operation, was almost significant (P = 0.06) in the univariate analysis, but was canceled in the multivariate setting by the recurrence-free interval. Again, FIGO stage, grade of the tumor, and patient age had no predictive value.
CONCLUSIONS: The authors conclude that radical surgical procedure can prolong survival times in patients with recurrent ovarian cancer. Patients who had a complete resection of cancer tissue in the primary operation or those who experienced a disease-free interval of more than 12 months after primary operation are most likely to benefit from second operation in recurrent ovarian cancer. Radical surgical procedure should be offered to these patients to enhance efficacy of second-line chemotherapy, which is of limited value in bulky recurrent disease.

Entities:  

Mesh:

Year:  1992        PMID: 1394042     DOI: 10.1002/1097-0142(19921015)70:8<2129::aid-cncr2820700820>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer.

Authors:  Nina A Bickell; Natalia Egorova; Monica Prasad-Hayes; Rebeca Franco; Elizabeth A Howell; Juan Wisnivesky; Partha Deb
Journal:  Am J Clin Oncol       Date:  2018-05       Impact factor: 2.339

Review 2.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  Ovarian cancer: the duplicity of CA125 measurement.

Authors:  Amer K Karam; Beth Y Karlan
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 4.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

Authors:  Rani Akhil Bhat; Yin Nin Chia; Yong Kuei Lim; Kwai Lam Yam; Cindy Lim; Melissa Teo
Journal:  Oman Med J       Date:  2015-09

Review 6.  Secondary cytoreduction for patients with recurrent ovarian cancer.

Authors:  Teresa P Díaz-Montes; Robert E Bristow
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

Review 7.  Quality of life in patients with ovarian cancer: current state of research.

Authors:  A Montazeri; J McEwen; C R Gillis
Journal:  Support Care Cancer       Date:  1996-05       Impact factor: 3.603

8.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

Authors:  R Y Zang; P Harter; D S Chi; J Sehouli; R Jiang; C G Tropé; A Ayhan; G Cormio; Y Xing; K M Wollschlaeger; E I Braicu; C A Rabbitt; H Oksefjell; W J Tian; C Fotopoulou; J Pfisterer; A du Bois; J S Berek
Journal:  Br J Cancer       Date:  2011-08-30       Impact factor: 7.640

9.  The role of secondary surgery in recurrent ovarian cancer.

Authors:  D Lorusso; M Mancini; R Di Rocco; R Fontanelli; F Raspagliesi
Journal:  Int J Surg Oncol       Date:  2012-08-05

10.  Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.

Authors:  Farr R Nezhat; Shaghayegh M Denoble; Jennifer E Cho; Douglas N Brown; Enrique Soto; Linus Chuang; Herbert Gretz; Prakash Saharia
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.